Ashton Thomas Private Wealth LLC Makes New Investment in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Ashton Thomas Private Wealth LLC purchased a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 400 shares of the company’s stock, valued at approximately $26,000.

Several other institutional investors also recently made changes to their positions in PBE. Covestor Ltd boosted its holdings in Invesco Biotechnology & Genome ETF by 24.2% in the first quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after acquiring an additional 186 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 1.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 13,862 shares of the company’s stock valued at $897,000 after purchasing an additional 256 shares in the last quarter. US Bancorp DE grew its holdings in shares of Invesco Biotechnology & Genome ETF by 1.8% during the 1st quarter. US Bancorp DE now owns 16,800 shares of the company’s stock worth $1,087,000 after purchasing an additional 300 shares during the period. Investment House LLC grew its holdings in shares of Invesco Biotechnology & Genome ETF by 6.3% during the 2nd quarter. Investment House LLC now owns 7,635 shares of the company’s stock worth $495,000 after purchasing an additional 450 shares during the period. Finally, GPS Wealth Strategies Group LLC acquired a new stake in Invesco Biotechnology & Genome ETF during the 2nd quarter worth approximately $30,000.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA PBE opened at $71.25 on Wednesday. Invesco Biotechnology & Genome ETF has a one year low of $52.47 and a one year high of $72.72. The company’s 50 day moving average price is $69.65 and its 200 day moving average price is $65.89. The firm has a market capitalization of $287.85 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.